[1] Li XX, Lu J, Luo DH, Huang BQ. The histone deacetylase activity of SIR2 and chromatin silencing. Hereditas (Beijing) , 2003, 25(4): 484-488. 李晓雪, 陆军, 罗巅辉, 黄百渠. 组蛋白去乙酰化酶SIR2与染色质沉默. 遗传, 2003, 25(4): 484-488.
[2] Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene , 2007, 26(37): 5310-5318.
[3] Lakshmaiah KC, Jacob LA, Aparna S, Lokanatha D, Saldanha SC. Epigenetic therapy of cancer with histone deacetylase inhibitors. J Cancer Res Ther , 2014, 10(3): 469- 478.
[4] Das GK, Shakespear MR, Iyer A, Fairlie DP, Sweet MJ. Histone deacetylases in monocyte/macrophage development, activation and metabolism: refining HDAC targets for inflammatory and infectious diseases. Clin Transl Immunol , 2016, 5(1): e62.
[5] Dong M, Ning ZQ, Xing PY, Xu JL, Cao HX, Dou GF, Meng ZY, Shi YK, Lu XP, Feng FY. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol , 2012, 69(6): 1413-1422.
[6] Rigby L, Muscat A, Ashley D, Algar E. Methods for the analysis of histone H3 and H4 acetylation in blood. Epigenetics , 2012, 7(8): 875-882.
[7] Kaypee S, Sudarshan D, Shanmugam MK, Mukherjee D, Sethi G, Kundu TK. Aberrant lysine acetylation in tumorigenesis: Implications in the development of therapeutics. Pharmacol Ther , 2016, doi:
10.1016/j.pharmthera.2016.01.011.
[8] Archin NM, Liberty AL, Kashuba AD, Choudhary, SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature , 2012, 487(7408): 482-485.
[9] Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, Winckelmann A, Palmer S, Dinarello C, Buzon M, Lichterfeld M, Lewin SR, Østergaard L, Søgaard OS. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV , 2014, 1(1): e13-e21.
[10] Søgaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, Kjaer AS, Schleimann MH, Denton PW, Hey-Cunningham WJ, Koelsch KK, Pantaleo G, Krogsgaard K, Sommerfelt M, Fromentin R, Chomont N, Rasmussen TA, Østergaard L, Tolstrup M, Siliciano RF. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog , 2015, 11(9): e1005142.
[11] Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ, Margolis DM. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol , 2009, 83(10): 4749-4756.
[12] Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J , 2006, 25(1): 139-149.
[13] Deeks SG. HIV: Shock and kill. Nature , 2012, 487(7408): 439-440.
(责任编委: 朱卫国)
